期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

利那鲁肽治疗2型糖尿病疗效观察 被引量：10

暂未订购
导出
摘要 目的观察利那鲁肽对2型糖尿病的临床疗效。方法将105例2型糖尿病患者随机分为二甲双胍组(55例)和利拉鲁肽组(50例),二甲双胍组在甘精胰岛素治疗的基础上加用二甲双胍,起始剂量0.25 g/次,3次/d,耐受后增至0.5 g/次;利拉鲁肽组在甘精胰岛素治疗的基础上加用利拉鲁肽,起始剂量0.6 mg,皮下注射,1次/d,耐受后增至1.2 mg。治疗12周后,比较两组患者腰围、体质量、空腹血糖(FPG)、餐后血糖(2 h PG)、糖化血红蛋白(HbA1C)、空腹胰岛素(FINS)、TG、TC、SBP和DBP。结果治疗12周后,两组血糖、HbA1C、胰岛素抵抗指数及血浆TG、TC均显著降低(P均<0.01);利拉鲁肽组腰围减小、体质量减轻、BMI减小(P均<0.01),而二甲双胍组没有变化(P均>0.05);利拉鲁肽组降低FPG、HbA1C、TG及TC的效果与二甲双胍组相当(P均>0.05),但降低2 h PG、改善胰岛素抵抗及降低SBP的效果优于二甲双胍组(P均<0.01)。结论利拉鲁肽可有效控制血糖,减轻患者体质量,改善胰岛素抵抗,降低SBP,更适合肥胖的2型糖尿病患者。
作者 王锋 陈刚 李雪侠
机构地区 徐州市肿瘤医院
出处 《山东医药》 CAS 2014年第4期44-46,共3页 Shandong Medical Journal
基金 江苏省徐州市社会发展项目(XZZD1249)
关键词 利拉鲁肽 糖尿病 2型 胰岛素 血糖
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献13

二级参考文献26

  • 1Buse JB,Henry RR,Han J,et al.Effects of exenatide on glycemic control over 30 weeks in sulfonylurea treated patients with type 2 diabetes[J].Diabetes Care,2004,27(11):2628-2635.
  • 2Kendall DM,RiddleMC,Rosenstock J,et al.Effects of exenatide on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea[J].Diabetes Care,2005,28(5):1083-1091.
  • 3Defronzo RA,Ratner RE,Han J,et al.Effects of exenatide on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes[J].Diabetes Care,2005,28 (5):1092-1100.
  • 4Blonde L,Klein EJ,Han J,et al.Interim analysis of the effects of exenatide treatment on A1C,weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes[J].Diabetes Obes Metab,2006,8(4):436-447.
  • 5Klonoff DC,Buse JB,Nielsen LL,et al.Exenatide effects on diabetes,obesity,cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years[J].Curr Med Res Opin,2008,24(1):275-286.
  • 6Yoon NM,Cavaghan MK,Brunelle RL,et al.Exenatide added to insulin therapy:a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting[J].Clin Ther,2009,31(7):1511-1523.
  • 7Sheffield CA,Kane MP,Busch RS,et al.Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus[J].Endocr Pract,2008,14(3):285-292.
  • 8Nayak UA,Govindan J,Baskar V,et al.Exenatide therapy in insulin-treated type 2 diabetes and obesity[J].QJM,2010,103(9):687-694.
  • 9American Diabetes Association.Standards of medical care in diabetes-2011[J].Diabetes Care,2011,34(Suppl 1):S11-S61.
  • 10Davies MJ,Donnelly R,Barnett AH,et al.Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes:results of the helping evaluate exenatide in patients with diabetes compared with long-acting insulin(HEELA)study[J].Diabetes Obes Metab,2009,11(12):1153-1162.

共引文献163

同被引文献87

  • 1Drucker D J, Nauck MA. The incretin system: glucagon-like peptide- 1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes [ J ]. Lancet, 2006,368 (9548) : 1696-1705.
  • 2Green BD, Gault VA, Mooney MH, et al. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide- 1 (7-36) amide have preserved biological activities in vitro conferring improved glucose- lowering action in vivo [J]. J Mol Endocrinol, 2003, 31 (3) : 529-540.
  • 3Kalra S. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibi- tor vildagliptin in the management of type 2 diabetes [J]. J Assoe Physicians India, 2011,59 (2) : 237-245.
  • 4Apovian CM, Bergenstal RM, Cuddihy RM, et al. Effects of exena- tide combined with lifestyle modification in patients with type 2 dia- betes[J]. Am J Med,2010,123(5) :468.
  • 5Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of ex- enatide and titrated insulin glargine in adult patients with type 2 di- abetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover nonin- feriority trial [ J ]. Clin Ther, 2007,29 ( 11 ) : 2333-2348.
  • 6Bergenstal R, Lewin A, Bailey T, et al. Efficacy and safety of bipha- sic insulin aspart 70/30 versus exenatide in subjects with type 2 di- abetes failing to achieve glycemic control with metformin and a sul- fonylurea[ J ]. Curr Med Res Opin, 2009,25 ( 1 ) : 65-75.
  • 7Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes [ J ]. Diabetes Care, 2004,27 ( 11 ) : 2628-2635.
  • 8Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exena- tide in basal insulin-treated patients with type 2 diabetes: a ran- domized, controlled trial [J]. Ann Intern Med, 2011, 15 (42) : 103-112.
  • 9Davies MJ, Donnelly R, Barnett AH, et al. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the helping evaluate exenatide in patients with diabetes compared with long- acting insulin (HEELA) study [ J ]. Diabetes Obes Metab, 2009,11 (12) : 1153-1162.
  • 10DeFronzo RA,Triplitt C, Qu Y, et al. Effects of exenatide plus rosi- glitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin [J]. Diabetes Care, 2010, 33 (5) :951-957.

引证文献10

二级引证文献40

山东医药
2014年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部